Replies to post #443660 on Anavex Life Sciences Corp (AVXL)

[tradeherpete]

Now we're playing catch up. Let's Gooooooo!

KarXT Is Expected to Launch in the U.S. for the Treatment of Schizophrenia in Adults with a Prescription Drug User Fee Act Date of September 26, 2024

[LakeshoreLeo1953]

The Someone (contained in your cut and paste) is Bristol Meyers.
They turned down Anavex licensing as I recall.

[couldbebetter]

$14 billion cash for a company with zero revenues!
That's about the same amount as being paid for US Steel!
A few years ago KRTX was trading under $15.

[Boopka]

Tred, it boggles the mind when we compare this to Missling stating that no partnerships will be done until AD approval to maximize shareholder value. At that point the value for AD might be a market cap increase of $20B plus you have to consider the other indications (Rett and possibly PDD) plus hiding in the weeds is 3-71 to possibly prevent AD. The valuation could be so high at that point that only those with the deepest pockets could afford a deal.

[abew4me]

Quote: Someone [Bristol Meyers] just paid 14b for a company offering a Muscarinic Receptor Agonist.

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company.
The Company creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline is primarily built on the therapeutic potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS), and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS.
The Company is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, as well as for the treatment of psychosis in Alzheimer's disease (AD). The Company is also engaged in developing its investigational TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and plan to provide details regarding the expected development of KAR-2618.